American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials
13 Dec 2022
Description
Dr. Elie Naddaf, MD interviews Dr. James Howard, MD about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis, highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster